Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Lo Coco

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Annals of Hematology|July 2, 2014
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia studyAntonio R Lucena-Araujo, Haesook T Kim, Rafael H Jacomo, et al.
Blood|October 3, 2015
High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Haesook T Kim, Carolina Thomé, et al.
Leukemia & Lymphoma|July 13, 2011
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patientsMichele Malagola, Cristina Skert, Marco Vignetti, et al.
Blood|July 12, 2019
Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Juan L Coelho-Silva, Diego A Pereira-Martins, et al.
Annals of Hematology|May 16, 2015
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studiesMiguel A Sanz, Pau Montesinos, Haesook T Kim, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Blood|January 16, 2013
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APLEduardo M Rego, Haesook T Kim, Guillermo J Ruiz-Argüelles, et al.
Cancers|October 30, 2020
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic LeukemiaIsabel Weinhäuser, Diego A Pereira-Martins, Cesar Ortiz, et al.
Blood Advances|October 13, 2020
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trialMaria Teresa Voso, Richard A Larson, Dan Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 TrialUwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Annals of Hematology|July 2, 2014
Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia studyAntonio R Lucena-Araujo, Haesook T Kim, Rafael H Jacomo, et al.
Blood|October 3, 2015
High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Haesook T Kim, Carolina Thomé, et al.
Leukemia & Lymphoma|July 13, 2011
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patientsMichele Malagola, Cristina Skert, Marco Vignetti, et al.
Blood|July 12, 2019
Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Juan L Coelho-Silva, Diego A Pereira-Martins, et al.
Annals of Hematology|May 16, 2015
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studiesMiguel A Sanz, Pau Montesinos, Haesook T Kim, et al.
Blood|August 10, 2019
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Alfonso Piciocchi, Anna Candoni, et al.
Blood|January 16, 2013
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APLEduardo M Rego, Haesook T Kim, Guillermo J Ruiz-Argüelles, et al.
Cancers|October 30, 2020
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic LeukemiaIsabel Weinhäuser, Diego A Pereira-Martins, Cesar Ortiz, et al.
Blood Advances|October 13, 2020
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trialMaria Teresa Voso, Richard A Larson, Dan Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 TrialUwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, et al.
Pageof 21